Our aim is to help our customers predict the immune response. Immunogenicity prediction is a key need in the field of biologics, particularly for cancer vaccines. We want to help our customers to identify "real" epitopes (those that will cause a T-cell response) from pools of potential neo-epitopes generated by sequencing data.
Conversely (e.g., protein/peptide-based therapeutics), there is often a need to predict if an unwanted immune response can occur.
At Immunitrack, we use our knowledge of MHC-epitope binding to aid in:
- De-immunization of biologics.
- Identification of stable epitopes that are a better predictor of immunogenicity than affinity alone.
- Development of a better antigenicity prediction software tool (PrDx).
The presentation below gives an overview of our capabilities and presents some case studies.